AstraZeneca PLC
AZNCF
$148.12
$0.760.52%
| Weiss Ratings | AZNCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Excellent | |||
| Risk Index | Weak | |||
| Risk Grade | D+ | |||
| Reward Grade | A- | |||
| Rating Factors | AZNCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Good | |||
| Growth Index | Excellent | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AZNCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.25 | |||
| Price History | AZNCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.22% | |||
| 30-Day Total Return | -0.40% | |||
| 60-Day Total Return | 14.14% | |||
| 90-Day Total Return | 15.99% | |||
| Year to Date Total Return | 10.76% | |||
| 1-Year Total Return | 9.26% | |||
| 2-Year Total Return | 8.86% | |||
| 3-Year Total Return | 9.01% | |||
| 5-Year Total Return | 71.01% | |||
| 52-Week High % Change | -15.73% | |||
| 52-Week Low % Change | 22.24% | |||
| Price | AZNCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $175.00 | |||
| 52-Week Low Price | $120.64 | |||
| 52-Week Low Price (Date) | Nov 18, 2024 | |||
| 52-Week High Price (Date) | Aug 30, 2024 | |||
| Valuation | AZNCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 229.16B | |||
| Enterprise Value | 255.03B | |||
| Price/Earnings (TTM) | 32.68 | |||
| Earnings Per Share (TTM) | 4.51 | |||
| Earnings Per Share Growth | 18.00% | |||
| Price/Earnings To Growth | 1.82 | |||
| Price/Sales (TTM) | 4.26 | |||
| Price/Book (Q) | 5.61 | |||
| Enterprise Value/Revenue (TTM) | 4.72 | |||
| Price | $148.12 | |||
| Enterprise Value/EBITDA (TTM) | 14.55 | |||
| Enterprise Value/EBIT | 19.78 | |||
| Market Cap Category | Mega Cap | |||
| Dividends and Shares | AZNCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.56B | |||
| Dividend Yield | 2.10% | |||
| Div. Per Share (Most Recent) | $2.10 | |||
| Dividend Per Share (TTM) | $3.10 | |||
| Payout Ratio (TTM) | 65.80% | |||
| Dividend Per Share (Most Recent) | $2.10 | |||
| Company Info | AZNCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 44 20 3749 5000 | |||
| Address | -- | |||
| Website | www.astrazeneca.com | |||
| Country | United Kingdom | |||
| Year Founded | 1992 | |||
| Profitability | AZNCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 23.87% | |||
| Profit Margin | 13.01% | |||
| Management Effectiveness | AZNCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 7.86% | |||
| Return on Equity | 17.59% | |||
| Income Statement | AZNCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 54.07B | |||
| Total Revenue (TTM) | 54.07B | |||
| Revenue Per Share | $34.62 | |||
| Gross Profit (TTM) | 44.44B | |||
| EBITDA (TTM) | 17.55B | |||
| EBIT (TTM) | 12.91B | |||
| Net Income (TTM) | 7.04B | |||
| Net Income Avl. to Common (TTM) | 7.04B | |||
| Total Revenue Growth (Q YOY) | 23.84% | |||
| Earnings Growth (Q YOY) | 56.41% | |||
| EPS Diluted (TTM) | 4.51 | |||
| EPS Diluted Growth (Q YOY) | 56.70% | |||
| Balance Sheet | AZNCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 5.53B | |||
| Cash Per Share (Q) | $3.54 | |||
| Total Current Assets (Q) | 25.83B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 40.87B | |||
| Current Ratio (Q) | 0.927 | |||
| Book Value Per Share (Q) | $26.30 | |||
| Total Assets (Q) | 104.04B | |||
| Total Current Liabilities (Q) | 27.87B | |||
| Total Debt (Q) | 30.46B | |||
| Total Liabilities (Q) | 63.16B | |||
| Total Common Equity (Q) | 40.79B | |||
| Cash Flow | AZNCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -7.98B | |||
| Cash from Financing (TTM) | -4.00B | |||
| Net Change in Cash (TTM) | -208.00M | |||
| Levered Free Cash Flow (TTM) | 8.42B | |||
| Cash from Operations (TTM) | 11.86B | |||
